Astellas Pharma

Basic Information

Stock Code
4503
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
March 1939
Listing Year
May 1949
Official Website
https://www.astellas.com/jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
JT, Kyowa Kirin, Takeda, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Hisamitsu Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings

Overview

Astellas Pharma is a leading Japanese pharmaceutical manufacturer founded in 1939 and one of the country's major pharmaceutical companies, with strengths in immunosuppressants and anticancer drugs.

Current Situation

Astellas Pharma recorded consolidated sales of approximately 1.2495 trillion yen and net profit of approximately 120.6 billion yen in the fiscal year ended March 2021, making it the second-largest in the domestic pharmaceutical industry after Takeda Pharmaceutical. Key products include the immunosuppressant Prograf and the urological medication Harnal, and it possesses competitiveness in oncology with antitumor agents such as Zospata. Through aggressive M&A, it has acquired overseas bio-ventures to introduce new drug discovery technologies and advance international expansion. Additionally, for sustainable corporate activities, it is committed to reducing environmental impact and social contributions, while its 2030 long-term strategy emphasizes strengthening new drug development and promoting global growth. In 2023, under Representative Director and President Naoki Okamura, it is focusing on management innovation and digitalization to strengthen its position within the industry.

Trivia

Interesting Facts

  • Founded in 1939 as Yamanouchi Pharmaceutical and born from the 2005 merger with Fujisawa Pharmaceutical.
  • Holds top-class market share in urology for many years.
  • In 2007, made a large acquisition of a U.S. bio-venture with antibody drug technology.
  • A global company with over 14,000 employees domestically and internationally.
  • The company name 'Astellas' means 'star' in Latin, symbolizing innovation and hope.
  • Previously received a sales suspension penalty from the UK Association of the British Pharmaceutical Industry.
  • Conducts biopharmaceutical business through strategic alliance with Amgen.
  • Actively invests in gene therapy and digital health beyond pharmaceuticals.
  • Aggressively pursued M&A to address the 2010 pharmaceutical industry issue.
  • Occupies an important position in the market as one of Japan's big five pharmaceutical companies.
  • The organ transplant drug Prograf accounts for a large portion of sales.
  • The company emblem is designed as a star-shaped combination of 'mountain' and Fujisawa's 'F'.
  • There was a patient death case during clinical trials for a rare disease gene therapy drug.
  • An incident occurred where a Chinese subsidiary executive was detained in connection with anti-espionage laws.
  • Utilizes online channels in addition to medical sites for sales.

Hidden Connections

  • Originally part of the Sanwa Group via former Fujisawa Pharmaceutical, maintaining long-term relationships with some client companies.
  • Through a joint venture with Amgen, closely collaborates with a U.S. company in the new biopharmaceutical market.
  • The sales suspension penalty from ABPI for UK pharmaceutical ethics issues attracted international attention.
  • Japan Master Trust Bank and Japan Custody Bank are listed as major shareholders, indicating strong ties with financial institutions.
  • Proprietary antibody drug platform technology serves as a key differentiator from domestic and international competitors.
  • The head office building in Nihonbashi Honcho, Chuo-ku, Tokyo, was newly built after the merger, contributing to refreshing the corporate image.
  • Academic and PR films planned by former companies are highly regarded in the industry.
  • While centered on prescription pharmaceuticals, some products are supplied to the market under other companies' brands through sales partnerships.

Future Outlook

Growth Drivers

  • Expansion of anticancer drug demand in global markets
  • Practical application and dissemination of gene therapy drugs
  • Utilization of advancements in AI and digital health technologies
  • Expansion of product portfolio across diverse treatment areas
  • Enhancement of sustainability responses to increase corporate value
  • Sales expansion in Asia and emerging markets
  • Commercialization of biopharmaceutical platforms
  • Rapid product development adapting to regulatory environments
  • Services aligned with patient-centered treatment trends
  • Strengthening new technology creation through industry-academia-government collaboration
  • Securing and developing highly skilled talent
  • Introduction and efficiency gains from smart manufacturing technologies

Strategic Goals

  • Achieve over 60% global sales ratio
  • Launch multiple innovative gene therapy products
  • Establish new revenue sources in digital health business
  • Reduce CO2 emissions by 50% to lessen environmental impact
  • Foster corporate culture promoting diversity and inclusion
  • Maintain R&D investment at 15% or more of sales
  • Establish position as world top-class immunology and oncology company
  • Build sustainable supply chains
  • Expand CSR activities with high social contribution
  • Complete organizational digital transformation

Business Segments

Pharmaceutical Development Support

Overview
Provides drug discovery and development support services to pharmaceutical companies and research institutions.
Competitiveness
Advanced R&D capabilities and broad technological foundation
Customers
  • Pharmaceutical companies
  • Biotechnology companies
  • Research institutions
  • Universities
  • CROs (Contract Research Organizations)
Products
  • Drug discovery technologies
  • Gene therapy drug development
  • Antibody drug technologies
  • Reagents and clinical testing reagents

API and Intermediate Manufacturing

Overview
Provides stable supply of APIs and intermediates to pharmaceutical companies domestically and internationally.
Competitiveness
High-quality manufacturing technology and rigorous quality control
Customers
  • Global pharmaceutical manufacturers
  • Domestic pharmaceutical manufacturers
Products
  • Active pharmaceutical ingredients
  • Intermediates
  • Biopharmaceutical manufacturing technologies

Sales and Marketing Support

Overview
Strongly supports product sales and information provision to medical institutions.
Competitiveness
Japan's largest sales network
Customers
  • Medical institutions
  • Pharmaceutical wholesalers
  • Pharmacy chains
Products
  • Pharmaceutical sales
  • Marketing support
  • Medical information provision

Licensing and Partnership Business

Overview
International licensing agreements for innovative technologies and products.
Competitiveness
Strengthened collaborations with research institutions worldwide
Customers
  • Global pharmaceutical companies
  • Bio-ventures
Products
  • New pharmaceutical licenses
  • Joint development projects

Contract Manufacturing (CMO)

Overview
High-quality systems capable of handling commissioned pharmaceutical production.
Competitiveness
Advanced manufacturing technologies and quality management systems
Customers
  • Pharmaceutical companies
  • Biotechnology companies
Products
  • Pharmaceutical API manufacturing
  • Biopharmaceutical manufacturing
  • Packaging manufacturing

Research Reagents and Testing Reagents Sales

Overview
Sales of essential reagents and tools for research activities.
Competitiveness
Diverse product lineup and high reliability
Customers
  • University labs
  • Medical institutions
  • Pharmaceutical development divisions
Products
  • Clinical testing reagents
  • Research reagents
  • Testing equipment and tools

Information Provision and Education Support Services

Overview
Provides product knowledge and the latest medical information to healthcare professionals.
Competitiveness
Highly specialized academic support system
Customers
  • Physicians
  • Pharmacists
  • Healthcare professionals
Products
  • Pharmaceutical information provision
  • Training programs
  • Academic support

Healthcare Product Sales

Overview
Develops and sells consumer health-related products.
Competitiveness
Brand strength and sales network
Customers
  • Consumers
  • Health facilities
  • Drugstores
Products
  • Over-the-counter drugs
  • Health foods
  • Supplements

Veterinary Pharmaceuticals

Overview
Develops and supplies pharmaceuticals for livestock and pets.
Competitiveness
Close ties with livestock farmers
Customers
  • Livestock producers
  • Veterinary hospitals
Products
  • Veterinary vaccines
  • Antibiotics
  • Antiparasitics

Overseas Market Expansion Support

Overview
Addresses local needs and expands business using overseas bases.
Competitiveness
Extensive experience in multinational markets
Customers
  • Overseas pharmaceutical partners
  • Local medical institutions
Products
  • Local pharmaceutical production
  • Sales partnerships
  • Product localization

Digital Health and AI Utilization

Overview
Innovates medical services through digital technologies.
Competitiveness
Integration of cutting-edge technology and medical expertise
Customers
  • Medical institutions
  • Patients
  • Development industry
Products
  • AI diagnostic support tools
  • Digital therapeutics solutions

Biopharmaceutical Joint Research

Overview
Aims to create innovative therapies through joint development.
Competitiveness
Strong biopharmaceutical technology and collaboration framework
Customers
  • Universities
  • Research institutions
  • Corporations
Products
  • Antibody drugs
  • Gene therapy drugs

Competitive Advantage

Strengths

  • Largest-scale sales organization in Japan
  • Expertise in immunosuppressants and anticancer drugs
  • Abundant R&D resources
  • Aggressive M&A strategy
  • Global expansion across multiple regions
  • Advanced biopharmaceutical technologies
  • Strong industry-academia collaboration framework
  • Rich patent portfolio
  • Solid financial base
  • Broad product portfolio
  • High manufacturing quality control capabilities
  • Diverse sales channels
  • Long-term growth strategy
  • Social trust and brand strength
  • Advanced clinical development capabilities

Competitive Advantages

  • High expertise in immunology and oncology drug development
  • Technology acquisition through extensive domestic and international M&A and partnerships
  • No. 2 sales scale and market influence in Japan's pharmaceutical industry
  • New drug creation through utilization of cutting-edge biotechnology
  • Global sales network
  • Efficiency of integrated research, manufacturing, and sales system
  • Promotion of sustainability-focused corporate activities
  • Market superiority from unique patents not held by competitors
  • Strength in diverse treatment area product lineup
  • Industry-leading clinical development track record
  • Information provision based on trusted relationships with healthcare professionals
  • Strong investment capacity backed by robust financial base
  • Flexibility to quickly respond to market needs
  • Pharmaceutical value creation using digital technologies
  • Quality and compliance aligned with international standards

Threats

  • Risk of revenue decline due to patent expirations on key drugs
  • Intensifying competition in the global pharmaceutical market
  • Increased development costs from stricter regulations
  • Development risks from increasing complexity of biopharmaceuticals
  • Challenges in responding to rapid changes in market needs
  • Instability in international situation such as U.S.-China trade friction
  • Emergence of innovative therapies from emerging companies
  • Price decline risks from healthcare cost-cutting pressures
  • Heightened social scrutiny on pharmaceutical ethics
  • Supply chain disruption risks
  • Intensifying competition for talent acquisition
  • Unforeseen social risks such as new infectious diseases

Innovations

2024: New antibody drug development for cancer immunotherapy

Overview
Developing novel antibody drugs using proprietary technology and advancing clinical trials.
Impact
Provides revolutionary options in cancer treatment

2023: Initiation of clinical trials for gene therapy drugs

Overview
Advancing development of gene therapy drugs for rare diseases and starting Phase 1 clinical trials.
Impact
Expected to improve patients' QOL

2022: Drug discovery efficiency improvement using AI

Overview
Successfully identified early drug candidate compounds using AI technology.
Impact
Achieves shorter drug discovery timelines and cost reductions

2021: Entry into digital health field

Overview
Developed a digital platform for patient data management and treatment support.
Impact
Improves treatment efficiency and patient convenience

2024: Introduction of low-environmental-impact manufacturing processes

Overview
Incorporating green chemistry technologies into manufacturing processes to reduce environmental impact.
Impact
Reduces CO2 emissions and achieves sustainable production

Sustainability

  • Formulation of greenhouse gas emission reduction plans
  • Improvement of waste recycling rates
  • Building sustainable supply chains
  • Promotion of diversity and inclusion
  • Collaborative environmental protection with local communities